Revotar Biopharmaceuticals AG / Revotar Biopharmaceuticals AG Starts Phase II Clinical Trial in COPD Patients with inhaled Bimosiamose processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Revotar Biopharmaceuticals AG today announced the...